ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
PLGA nanoparticles encapsulating fibroblast growth factor 21 alleviate acetaminophen-induced acute liver injury.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The short half-life of fibroblast growth factor 21 (FGF21) in vivo limits its clinical application in acetaminophen (APAP)-induced acute liver injury (ALI). This study aimed to construct a novel PLGA-based nanoparticle delivery system for FGF21 and to investigate its protective effects and underlying mechanisms in APAP-induced ALI. PLGA-FGF21 nanoparticles were prepared using a double-emulsion solvent evaporation method and characterized by transmission electron microscopy and Zetasizer Nano for morphology, size, and stability. Their release profile and cytotoxicity were evaluated in vitro using AML12 cells, while hepatoprotective effects were assessed in an APAP-induced ALI mouse model. Histopathology, biochemical assays, immunofluorescence, and Western blot were employed to examine liver function, oxidative stress, and molecular mechanisms. The nanoparticles displayed uniform spherical morphology with an average size of 222.04 ± 1.08 nm and remained stable for 7 days in aqueous suspension. Encapsulation conferred sustained-release properties, and the particles showed no cytotoxicity while maintaining biological activity for at least 28 days. In vivo, PLGA-FGF21 significantly alleviated APAP-induced liver damage, reduced serum ALT and AST, and exhibited superior hepatoprotective efficacy compared with free FGF21. Furthermore, it suppressed inflammatory responses by decreasing TNF-α and MDA levels, while enhancing antioxidant defenses through increased SOD activity. Mechanistically, PLGA-FGF21 activated the PGC-1α/Nrf2/HO-1 signaling pathway, contributing to enhanced anti-inflammatory and antioxidant effects. PLGA-FGF21 nanoparticles provide potent protection against APAP-induced ALI by reducing inflammation and oxidative stress, which may be associated with activation of the PGC-1α/Nrf2 signaling pathway, offering a promising strategy for FGF21-based therapy in liver injury.
Indexed as
Identifiers
41838132What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.